SEC Form 4 · Rule 10b5-1 trading plans
Apellis Pharmaceuticals, Inc. (APLS)
- 9Trades filed under a plan
- 1Plan adoption dates stated
- 2Quarterly results prints on file
- 0Trades in the days before a print
In the 2025 filing year, Apellis Pharmaceuticals, Inc. filed 7 Form 4 statements whose footnotes name a Rule 10b5-1 trading plan, by 4 reporting owners, covering 9 transactions filed under those plans and 247,911 shares. 1 of those filings carry the SEC's own AFF10B5ONE adoption flag; the other 6 name a plan in a footnote and carry no flag. 2 results prints are on file in the same window, which is what makes the interval below measurable.
Trades filed under a plan in Apellis Pharmaceuticals, Inc. 9
- Francois Cedric — 2025-07-14 · S · 137,465 shares
- Francois Cedric — 2025-07-15 · S · 1,900 shares
- Watson David O. — 2025-07-16 · S · 5,000 shares
- Francois Cedric — 2025-07-17 · S · 19,725 shares
- Watson David O. — 2025-08-18 · S · 5,000 shares
- Sullivan Timothy Eugene — 2025-09-08 · S · 32,729 shares
- Sullivan Timothy Eugene — 2025-09-08 · S · 10,000 shares
- Watson David O. — 2025-09-16 · S · 5,000 shares
- Dunlop A. Sinclair — 2025-09-19 · S · 31,092 shares
Plan adoption dates stated in Apellis Pharmaceuticals, Inc. 1
- 2025-06-20 — stated in 1 filing
Quarterly results prints on file in Apellis Pharmaceuticals, Inc. 2
- 2025-01-13
- 2026-01-12
Trades in the days before a print in Apellis Pharmaceuticals, Inc. 0
- 115 days before the 2026-01-12 print — 2025-09-19 · S · Dunlop A. Sinclair · 31,092 shares
- 118 days before the 2026-01-12 print — 2025-09-16 · S · Watson David O. · 5,000 shares
- 126 days before the 2026-01-12 print — 2025-09-08 · S · Sullivan Timothy Eugene · 32,729 shares
- 126 days before the 2026-01-12 print — 2025-09-08 · S · Sullivan Timothy Eugene · 10,000 shares
- 147 days before the 2026-01-12 print — 2025-08-18 · S · Watson David O. · 5,000 shares
- 179 days before the 2026-01-12 print — 2025-07-17 · S · Francois Cedric · 19,725 shares
- 180 days before the 2026-01-12 print — 2025-07-16 · S · Watson David O. · 5,000 shares
- 181 days before the 2026-01-12 print — 2025-07-15 · S · Francois Cedric · 1,900 shares
- 182 days before the 2026-01-12 print — 2025-07-14 · S · Francois Cedric · 137,465 shares
Interval to the next reported results date
For each transaction filed under a plan, the days between the transaction date and the company’s next results print. These are the dates the filings state, printed as an interval; the page draws no conclusion from them.
- 0Within 5 days of a print
- 0Within 10 days of a print
- 115Shortest interval, in days
- 0Trades with no later print on file
Adoption dates, as the filings state them
- 2025-06-20 stated in 1 filing
As the filings state it: “10b5-1 trading plan adopted by Epidarex Capital I LP ("Epidarex") on June 20, 2025”
Reported results dates on file
- 2025-01-13
- 2026-01-12
A proxy statement is on file for this company in the same window (2025-04-23), which is where a company states its own trading policy.
Other companies with plan records
- BRISTOL MYERS SQUIBB CO 1
- FMC CORP 2
- ELI LILLY & Co 4
- ABEONA THERAPEUTICS INC. 2
- HEXCEL CORP /DE/ 2
- TEVA PHARMACEUTICAL INDUSTRIES LTD 12
- Lifevantage Corp 1
- IONIS PHARMACEUTICALS INC 29
- VERTEX PHARMACEUTICALS INC / MA 22
- ARROWHEAD PHARMACEUTICALS, INC. 9
Order the document
Every company with plan records →
Form 4 statements and their footnotes from the SEC’s EDGAR full-text search, and this company’s results dates, industry classification and state of incorporation from the SEC submissions API. The page prints the dates the filings state and the interval between them; it draws no conclusion from them.